MA-IBASIS
18.5.2021 07:02:13 CEST | Business Wire | Press release
iBASIS , the leading provider of communications solutions for operators and digital players worldwide, today announced the launch of iBASIS Carrier Voice for Teamwork , enabling carriers such as China Telecom Europe (CTE), a leading provider to European multinationals, to serve Enterprise customers with much needed cloud-based PBX functionality for their collaboration platforms.
With the massive shift toward Microsoft Teams triggered by COVID-19, carriers have an immediate opportunity to seize new Enterprise revenues by delivering a proven solution to bring voice to Microsoft Teams. iBASIS Carrier Voice for Teamwork™ provides global service availability, from and to the cloud via 2-way PSTN numbers, enabling native voice service in 60+ markets for global termination to help carriers respond to their local Enterprise demand. Carriers have the option to keep their own numbers to avoid porting or leverage iBASIS for local numbers.
The solution is built on iBASIS’ established wholesale leadership to drive voice capabilities for Microsoft Teams and deliver proven performance ensuring that carriers like CTE gain extremely quick time-to-market with its pay-as-you-go model, flexible pricing plans, easy configuration, and self-service portal.
”iBASIS Carrier Voice for Teamwork provides China Telecom Europe (CTE) with voice for Microsoft Teams to respond to and support their Enterprise customers with more effective collaboration across the globe ,” says Edwin van Ierland, Chief Commercial Officer and Chief Operating Officer at iBASIS. “Leveraging our reach, scale, independence, and leading technology partnerships, CTE was able to rapidly roll out easy-to-deploy capabilities to meet fast-moving market conditions. ”
“Our value proposition at China Telecom Europe (CTE) is differentiated by our holistic ICT approach, ” adds Nathan Li, Deputy Director, Voice & Messaging, China Telecom Europe. “The iBASIS Carrier Voice for Teamwork™ provides us with a proven, highly flexible solution with a customer-friendly commercial structure that helps us to quickly adapt to new opportunities for business growth. We trust iBASIS to continue delivering on quality, opportunity, and partnership. ”
iBASIS plans to broaden Carrier Voice for Teamwork to other tools, like Slack, Zoom, and WebEx. The solution is part of iBASIS’ larger Carrier Cloud Communications portfolio, which includes cloud numbering solutions, international numbers, global voice termination, and Communications Platform as a Service (CPaaS). iBASIS continues to enable carriers with opportunities to regain control and outperform throughout the large-scale transformations of their Enterprise customers.
Please visit us online for more information about iBASIS Carrier Voice for Teamwork .
ABOUT iBASIS
iBASIS is the leading communications solutions provider enabling operators and digital players worldwide to perform and transform. Powered by Tofane Global , iBASIS is the first independent communications specialist, ranking third largest global wholesale voice operator, and Top 3 LTE IPX vendor with 700+ LTE destinations. iBASIS today serves 1,000+ customers across 18 offices worldwide. For more information, please visit iBASIS.com .
ABOUT CHINA TELECOM (EUROPE) LTD.
China Telecom (Europe) Ltd . (CTE) provides integrated telecommunications and technology services as local, regional, and global solutions for Chinese, Asian, and European multinational corporations. CTE’s unrivaled knowledge of the Chinese market and regional offices across Europe make CTE an ideal partner for European and Asian businesses looking to work in China and Asia. Please visit us online for more information at chinatelecomeurope.com .
iBASIS® and other marks as indicated are the trademarks or registered trademarks of iBASIS, Inc. or other companies in the United States and other countries.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210517005948/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom